• Je něco špatně v tomto záznamu ?

Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates

J. Mandíková, M. Volková, P. Pávek, M. Česnek, Z. Janeba, V. Kubíček, F. Trejtnar,

. 2013 ; 311 (3) : 135-146.

Jazyk angličtina Země Irsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14040661

Grantová podpora
NT12398 MZ0 CEP - Centrální evidence projektů

Members of acyclic nucleoside phosphonates (ANPs) possess antiviral and antiproliferative activities. However, several clinically important ANPs may cause renal injury, most likely due to their active accumulation in the renal tubular cells. The goal of this study was to investigate in vitro relationships between the affinity of several structurally related potent ANPs to selected human transporters and their cytotoxicity. SLC (solute carrier family) transporters (hOAT1, hOCT2, hCNT2, hCNT3) and ABC (ATP-binding cassette) transporters (MDR1, BCRP), which are typically expressed in the kidney, were included in the study. The transport and toxic parameters of the tested compounds were compared to those of two clinically approved ANPs, adefovir and tenofovir. Transport studies with transiently transfected cells were used as the main method in the experiments. Most of the ANPs studied showed the potency to interact with hOAT1. GS-9191, a double prodrug of PMEG, displayed an affinity for hOAT1 comparable with that of adefovir and tenofovir. No significant interaction of the tested ANPs with hOCT2, hCNT2 and hCNT3 was observed. Only GS-9191 was found to be a strong inhibitor for both MDR1 and BCRP. PMEO-DAPy showed the potency to interact with MDR1. Most of the tested substances caused a significant decrease in cellular viability in the cells transfected with hOAT1. Only with the exclusion of GS-9191, a relatively lipophilic compound, did the in vitro cytotoxicity of the ANPs closely correspond to their potential to interact with hOAT1. The increased cytotoxicity of the studied ANPs found in OAT1 transfected cells was effectively reduced by OAT inhibitors probenecid and quercetin. The higher cytotoxicity of the compounds with affinity to hOAT1 proved in the inhibitory experiments evidences that ANPs are not only inhibitors but also substrates of hOAT1. Any clear relationship between the potency of ANPs to inhibit the studied efflux transporters and their cytotoxicity was not demonstrated. In conclusion, the study documented that among the studied transporters hOAT1 seems to be the decisive determinant for renal handling in most of the tested ANPs. This transporter may also play an important role in the mechanism of their potential cytotoxic effects. These facts are in good accordance with previous findings in the clinically used ANPs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14040661
003      
CZ-PrNML
005      
20170428115429.0
007      
ta
008      
140107s2013 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.tox.2013.07.004 $2 doi
035    __
$a (PubMed)23856525
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Mandíková, Jana $7 xx0159490
245    10
$a Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates / $c J. Mandíková, M. Volková, P. Pávek, M. Česnek, Z. Janeba, V. Kubíček, F. Trejtnar,
520    9_
$a Members of acyclic nucleoside phosphonates (ANPs) possess antiviral and antiproliferative activities. However, several clinically important ANPs may cause renal injury, most likely due to their active accumulation in the renal tubular cells. The goal of this study was to investigate in vitro relationships between the affinity of several structurally related potent ANPs to selected human transporters and their cytotoxicity. SLC (solute carrier family) transporters (hOAT1, hOCT2, hCNT2, hCNT3) and ABC (ATP-binding cassette) transporters (MDR1, BCRP), which are typically expressed in the kidney, were included in the study. The transport and toxic parameters of the tested compounds were compared to those of two clinically approved ANPs, adefovir and tenofovir. Transport studies with transiently transfected cells were used as the main method in the experiments. Most of the ANPs studied showed the potency to interact with hOAT1. GS-9191, a double prodrug of PMEG, displayed an affinity for hOAT1 comparable with that of adefovir and tenofovir. No significant interaction of the tested ANPs with hOCT2, hCNT2 and hCNT3 was observed. Only GS-9191 was found to be a strong inhibitor for both MDR1 and BCRP. PMEO-DAPy showed the potency to interact with MDR1. Most of the tested substances caused a significant decrease in cellular viability in the cells transfected with hOAT1. Only with the exclusion of GS-9191, a relatively lipophilic compound, did the in vitro cytotoxicity of the ANPs closely correspond to their potential to interact with hOAT1. The increased cytotoxicity of the studied ANPs found in OAT1 transfected cells was effectively reduced by OAT inhibitors probenecid and quercetin. The higher cytotoxicity of the compounds with affinity to hOAT1 proved in the inhibitory experiments evidences that ANPs are not only inhibitors but also substrates of hOAT1. Any clear relationship between the potency of ANPs to inhibit the studied efflux transporters and their cytotoxicity was not demonstrated. In conclusion, the study documented that among the studied transporters hOAT1 seems to be the decisive determinant for renal handling in most of the tested ANPs. This transporter may also play an important role in the mechanism of their potential cytotoxic effects. These facts are in good accordance with previous findings in the clinically used ANPs.
650    _2
$a zvířata $7 D000818
650    _2
$a antivirové látky $x farmakologie $7 D000998
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a psi $7 D004285
650    _2
$a HeLa buňky $7 D006367
650    _2
$a lidé $7 D006801
650    _2
$a ledviny $x metabolismus $7 D007668
650    _2
$a buňky MDCK $7 D061985
650    _2
$a membránové transportní proteiny $x metabolismus $7 D026901
650    _2
$a organofosfáty $x farmakologie $7 D010755
650    _2
$a puriny $x farmakologie $7 D011687
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Volková, Marie $7 xx0213299
700    1_
$a Pávek, Petr $7 xx0093070
700    1_
$a Česnek, Michal $7 xx0119826
700    1_
$a Janeba, Zlatko $7 xx0104656
700    1_
$a Kubíček, Vladimír $7 _AN062437
700    1_
$a Trejtnar, František $7 xx0143079
773    0_
$w MED00004533 $t Toxicology $x 1879-3185 $g Roč. 311, č. 3 (2013), s. 135-146
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23856525 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140107 $b ABA008
991    __
$a 20170428115750 $b ABA008
999    __
$a ok $b bmc $g 1005057 $s 839173
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 311 $c 3 $d 135-146 $i 1879-3185 $m Toxicology $n Toxicology $x MED00004533
GRA    __
$a NT12398 $p MZ0
LZP    __
$a Pubmed-20140107

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...